Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the CHMP’s Positive Opinion for Dystrophic Epidermolysis Bullosa (DEB)
Shots:
- The CHMP has recommended Vyjuvek (B-VEC) for treating wounds in DEB pts with COL7A1 mutations from birth. The EC's decision is expected in Q2’25, with launch anticipated under the trade name Vyjuvek in 30 EEA states—Germany in mid-2025 & France in late 2025
- Opinion was based on various clinical data, incl. P-I/II (GEM-1) & P-III (GEM-3) trial data published in Nature Medicine & The NEJM, respectively, showing successful COL7A1 gene delivery & durable wound closure after topical application
- Long-term safety & efficacy were supported by the US OLE trial & real-world data since Vyjuvek's US launch in 2023
Ref: Krystal Biotech | Image: Krystal Biotech
Related News:- ALK Reports US FDA Approval of Odactra to Treat Children with House Dust Mite Allergy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
